Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Time to Buy?

Key Points

• Theravance Biopharma stock rose by 3.4%, reaching $12.84 during mid-day trading, with approximately 240,577 shares exchanged.
• Analysts have mixed outlooks, with BTIG Research raising its price target to $25.00 while Wall Street Zen downgraded the stock to a "hold" rating.
• The company's recent quarterly earnings beat expectations significantly, reporting $1.08 earnings per share and $26.20 million in revenue, exceeding analyst estimates.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shot up 3.4% during mid-day trading on Thursday . The company traded as high as $12.84 and last traded at $12.84. 240,577 shares traded hands during trading, a decline of 5% from the average session volume of 253,079 shares. The stock had previously closed at $12.42.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. BTIG Research boosted their target price on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, June 27th. Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research note on Tuesday, June 17th. Finally, Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat, Theravance Biopharma has a consensus rating of "Strong Buy" and a consensus price target of $21.33.

Theravance Biopharma Price Performance

The company's 50-day moving average price is $11.30 and its 200-day moving average price is $10.05. The company has a market cap of $677.34 million, a P/E ratio of 56.04 and a beta of 0.01.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the sale, the senior vice president directly owned 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 44,000 shares of company stock worth $491,800. Insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Aquatic Capital Management LLC acquired a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $25,000. GAMMA Investing LLC increased its holdings in shares of Theravance Biopharma by 1,201.8% during the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 3,281 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after acquiring an additional 781 shares during the last quarter. AQR Capital Management LLC acquired a new position in Theravance Biopharma in the 1st quarter worth about $101,000. Finally, ClearAlpha Technologies LP bought a new position in Theravance Biopharma in the fourth quarter valued at about $109,000. Institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.